TY - JOUR
TI - Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial
AU - Amerikanou, C.
AU - Kanoni, S.
AU - Kaliora, A.C.
AU - Barone, A.
AU - Bjelan, M.
AU - D'Auria, G.
AU - Gioxari, A.
AU - Gosalbes, M.J.
AU - Mouchti, S.
AU - Stathopoulou, M.G.
AU - Soriano, B.
AU - Stojanoski, S.
AU - Banerjee, R.
AU - Halabalaki, M.
AU - Mikropoulou, E.V.
AU - Kannt, A.
AU - Lamont, J.
AU - Llorens, C.
AU - Marascio, F.
AU - Marascio, M.
AU - Roig, F.J.
AU - Smyrnioudis, I.
AU - Varlamis, I.
AU - Visvikis-Siest, S.
AU - Vukic, M.
AU - Milic, N.
AU - Medic-Stojanoska, M.
AU - Cesarini, L.
AU - Campolo, J.
AU - Gastaldelli, A.
AU - Deloukas, P.
AU - Trivella, M.G.
AU - Francino, M.P.
AU - Dedoussis, G.V.
AU - On behalf of MAST4HEALTH consortium
JO - Molecular Nutrition and Food Research
PY - 2021
VL - 65
TODO - 10
SP - null
PB - John Wiley and Sons Inc
SN - null
TODO - 10.1002/mnfr.202001178
TODO - mastic;  mastiha;  placebo, adult;  aged;  body mass;  clinical trial;  complication;  controlled study;  dietary supplement;  double blind procedure;  drug effect;  dysbiosis;  female;  Greece;  human;  intestine flora;  Italy;  liver;  male;  microbiology;  middle aged;  multicenter study;  nonalcoholic fatty liver;  obesity;  pathology;  pathophysiology;  randomized controlled trial;  Serbia, Adult;  Aged;  Body Mass Index;  Dietary Supplements;  Double-Blind Method;  Dysbiosis;  Female;  Gastrointestinal Microbiome;  Greece;  Humans;  Italy;  Liver;  Male;  Mastic Resin;  Middle Aged;  Non-alcoholic Fatty Liver Disease;  Obesity;  Placebos;  Serbia
TODO - Scope: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease with poor therapeutic strategies. Mastiha possesses antioxidant/anti-inflammatory and lipid-lowering properties. The authors investigate the effectiveness of Mastiha as a nonpharmacological intervention in NAFLD. Methods and Results: Ninety-eight patients with NAFLD in three countries (Greece, Italy, Serbia) are randomly allocated to either Mastiha or Placebo for 6 months, as part of a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. The authors assess NAFLD severity via magnetic resonance imaging (MRI) scanning and LiverMultiScan technique and evaluate the effectiveness of Mastiha through medical, anthropometric, biochemical, metabolomic, and microbiota assessment. Mastiha is not superior to Placebo on changes in iron-corrected T1 (cT1) and Liver Inflammation Fibrosis score (LIF) in entire patient population; however, after BMI stratification (BMI ≤ 35 kg m-2 and BMI > 35 kg m-2), severely obese patients show an improvement in cT1 and LIF in Mastiha versus Placebo. Mastiha increases dissimilarity of gut microbiota, as shown by the Bray-Curtis index, downregulates Flavonifractor, a known inflammatory taxon and decreases Lysophosphatidylcholines-(LysoPC) 18:1, Lysophosphatidylethanolamines-(LysoPE) 18:1, and cholic acid compared to Placebo. Conclusion: Mastiha supplementation improves microbiota dysbiosis and lipid metabolite levels in patients with NAFLD, although it reduces parameters of liver inflammation/fibrosis only in severely obese patients. © 2021 Wiley-VCH GmbH
ER -